In this episode of Investor Connect, Hall welcomes by Laura Hilty, Principal at HealthX Ventures and Chief Strategy Officer at Ignite Data, to discuss her path from Epic to building and launching seven software products at a clinical research startup, supporting acquisitions, and ultimately seeing the business sold to Blackstone for $5B—before moving into early-stage health tech investing.

Laura shares how digital health opportunities are shifting as Epic expands into AI, creating new investment risk and pushing startups toward deep niches and tech-enabled services Epic won't replicate, like devices or clinician staffing. We also cover the FDA's push toward real-time clinical trials and questions around participant-level data, plus innovations addressing clinician shortages through automation and peer support, including Sober Sidekick's relapse prediction.

Laura closes with advice on proving product-market fit before VC, defining moats in an AI-driven world, and avoiding overly frothy early valuations.

Visit HealthX Ventures at www.healthxventures.com/

Reach out to at www.linkedin.com/in/laura-hilty001/

________________________________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https:/_/tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.